Zhang Fengchun

Founder of the Rheumatology Department at PUMCH. Led the development of China's first domestic innovative drug for systemic lupus erythematosus — Telitacicept (泰它西普). In clinical trials, 67%+ of patients achieved significant improvement, with results published in the New England Journal of Medicine. This breakthrough offers hope for countless lupus patients to reduce or discontinue long-term corticosteroid use. Also a nationally recognized authority on Sjogren syndrome, rheumatoid arthritis, and other autoimmune diseases.